Business
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
MOUNTAIN VIEW, Calif., May 02, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune.
About this update from Aditxt, Inc.
[{"type":"text","content":"Event Begins Today at 11:30 a.m. ET","length":35,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 02, 2025--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune.","length":458,"tagName":"p"},{"type":"text","content":"Event Details:Title: Aditxt Weekly UpdateDate: Friday, May 2, 2025Time: 11:30 a.m. ETLocation: Virtual (Zoom)Registration: Click here to register","length":150,"tagName":"p"},{"type":"text","content":"About Adimune","length":13,"tagName":"p"},{"type":"text","content":"Adimune is a pre-clinical stage biopharmaceutical company pioneering a new class of immune modulation therapies designed to restore natural immune tolerance. Adimune’s mission is to advance immune health by providing targeted, long-term solutions that minimize reliance on chronic immunosuppression—transforming treatment for autoimmune diseases and organ transplantation.","length":372,"tagName":"p"},{"type":"text","content":"One of Adimune’s innovations is ADI-100™, a first-in-class Apoptotic DNA Immunotherapy™ that mimics the body’s natural mechanisms for maintaining immune tolerance. This proprietary platform uses nucleic acid technology to deliver two coordinated signals: one encoding BAX, a protein that promotes targeted apoptosis, and another encoding a modified disease-specific antigen to re-establish immune tolerance.","length":407,"tagName":"p"},{"type":"text","content":"To learn more and view the corporate presentation, please visit adimune.com.","length":76,"tagName":"p"},{"type":"text","content":"About ADI-100","length":13,"tagName":"p"},{"type":"text","content":"ADI-100™ is an investigational antigen-specific gene therapy that consists of two DNA molecules designed to restore immune tolerance in autoimmune diseases or to induce tolerance to transplanted organs. This approach is designed to retrain the immune system to recognize antigens as "self" without relying on immunosuppression, offering the possibility of significant safety and effic...